Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years
Main finding · Incident goutResult — go to the resultRelative risk 1.03 95 % CI 0.81–1.29Authors' conclusion
In a population of US adults aged ≥50 years, there was no statistically significant increase in the risk of gout during the 30 days immediately after RZV exposure, compared with a subsequent 30-day CW.
Study context
- Population
- US health plan members aged ≥50 years with recombinant zoster vaccine (RZV) exposure followed by incident gout within 60 days461,323 received ≥1 RZV dose
- Participants
- 302 members
- Exposure
- Risk window vs control window
- Outcome
- Incident gout following any RZV dose
- Follow-up
- 60 days
Methodological detailsself-controlled risk interval (SCRI) design, real-world safety study, administrative claims data, conditional Poisson model
- Self-controlled risk interval (SCRI) design
- Real-world safety study
- Administrative claims data
- Conditional Poisson model
Main finding
Incident gout
Relative risk
1.03
95 % CI 0.81–1.29
Events by group
RWvs CW
RR 1.03 (95 % CI 0.81–1.29)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Sensitivity analyses (dose 1, dose 2, compliant dose spacing, seasonality, pre-COVID-19 era)
- All sensitivity analyses had consistent results, with no association of RZV with incident gout
Original publication
Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years. Semin Arthritis Rheum. Published 14 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →